腸道菌群及其代謝物在慢加急性肝衰竭發(fā)生發(fā)展中的作用
摘要:慢加急性肝衰竭(ACLF)病情兇險(xiǎn),發(fā)病迅速,短期病死率高。腸道菌群及其代謝物與ACLF發(fā)生發(fā)展和發(fā)病機(jī)制之間密切相關(guān)。ACLF進(jìn)展過程中,腸道完整性破壞,腸道微生態(tài)及其代謝物失調(diào),介導(dǎo)免疫紊亂,進(jìn)而加重全身炎癥性反應(yīng)。本文旨在闡明腸道菌群及其代謝物在ACLF發(fā)展過程中的作用和相關(guān)治療策略。
關(guān)鍵詞:胃腸道微生物組;代謝;慢加急性肝功能衰竭
基金項(xiàng)目:國家中醫(yī)藥管理局高水平中醫(yī)藥重點(diǎn)學(xué)科建設(shè)項(xiàng)目(zyyzdxk-2023005);首都衛(wèi)生發(fā)展科研專項(xiàng)(首發(fā)2024-1-2173);第七批全國老中醫(yī)藥專家學(xué)術(shù)經(jīng)驗(yàn)繼承工作;北京中醫(yī)藥科技發(fā)展資金項(xiàng)目(BJZYYB-2023-06);北京市自然科學(xué)基金面上項(xiàng)目(7232272)
Effect of intestinal flora and metabolites on the development and progression of acute-on-chronic liver failure
SHI Ke,ZHANG Qun,WANG Xianbo,F(xiàn)ENG Ying
Center of Integrative Medicine,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China
Corresponding author:WANG Xianbo,wangxianbo638@163.com (ORCID:0000-0002-3593-5741)
Abstract:Acute-on-chronic liver failure (ACLF) is a dangerous disease with severe conditions,rapid progression,and high short-term mortality. Intestinal flora and metabolites are closely associated with the development,progression,and pathogenesis of ACLF. During the development of ACLF,the destruction of intestinal integrity and the dysregulation of intestinal microecology and its metabolites mediate immune disturbance and thus aggravate systemic inflammatory response. This article elaborates on the role of intestinal flora and metabolites in the development and progression of ACLF and related therapeutic strategies.
Key words:Gastrointestinal Microbiome;Metabolism;Acute-On-Chronic Liver Failure
Research funding:Construction Project of High-level Key Disciplines of Traditional Chinese Medicine of National Administration of Traditional Chinese Medicine (zyyzdxk-202300);Capital’s Funds for Health mprovement and Research (CFH2024-1-2173);Seventh Batch of National Traditional Chinese Medicine Experts Academic Experience Inheritance Program;Beijing Traditional Chinese Medicine Technology Development Fund Project (BJZYYB-2023-06);Beijing Municipal Natural Science Foundation (7232272)
慢加急性肝衰竭(acute-on-chronic liver failure,ACLF)是在慢性肝病基礎(chǔ)上,多種急性打擊導(dǎo)致的肝功能急性嚴(yán)重受損,短期內(nèi)可出現(xiàn)多器官功能衰竭[1]。(剩余18208字)
- 開拓創(chuàng)新、協(xié)同攻關(guān) 助力人血白...
- 白蛋白生理功能再認(rèn)識(shí)...
- 人血白蛋白在肝硬化及其并發(fā)癥中...
- 基因工程人血清白蛋白的研發(fā)與應(yīng)...
- 白蛋白臨床試驗(yàn)設(shè)計(jì)中的統(tǒng)計(jì)學(xué)考...
- 肝硬化患者糞菌移植治療指南...
- 肝內(nèi)膽管癌精準(zhǔn)檢測(cè)專家共識(shí)(2...
- 《2024年國際酒精相關(guān)肝病專...
- 非酒精性脂肪性肝病中醫(yī)/中西醫(yī)...
- 微RNA-128-3p、沉默信...
- 非酒精性脂肪性肝炎小鼠模型肝組...
- 基于代謝組學(xué)探討益氣養(yǎng)陰解毒化...
- 硝酸甘油控制性低中心靜脈壓技術(shù)...
- Go-ichi-ni-san復(fù)...
- 沒食子酸對(duì)人肝癌HepG2細(xì)胞...
- 芍藥苷對(duì)棕櫚酸誘導(dǎo)的HepG2...
- 美羅培南相關(guān)肝損傷的影響因素及...
- 經(jīng)口膽胰管鏡聯(lián)合內(nèi)鏡逆行胰膽管...
- 基于自動(dòng)化機(jī)器學(xué)習(xí)構(gòu)建膽總管結(jié)...
- 胰腺癌中醫(yī)證候分布規(guī)律及影響因...
- 巨型肝血管平滑肌脂肪瘤伴包膜下...
- 藥物誘導(dǎo)的自身免疫樣肝炎的臨床...
- 氨基酸代謝在自身免疫性肝炎中的...
- 腸道菌群與乙型肝炎肝硬化...
- 終末期肝病模型(MELD)評(píng)分...
- 終末期肝病間充質(zhì)干細(xì)胞歸巢能力...
- 腸道菌群及其代謝物在慢加急性肝...
- 肝衰竭腸道屏障損傷與環(huán)鳥苷酸-...
- 經(jīng)內(nèi)鏡逆行胰膽管造影術(shù)后消化道...
- 膽-腸軸在肝內(nèi)膽管癌發(fā)生發(fā)展中...
- 肝內(nèi)膽管癌間質(zhì)-免疫微環(huán)境內(nèi)成...
- Gut|肝臟免疫微環(huán)境失衡驅(qū)動(dòng)...
- Hepatology Inte...
- Hepatology|多維度解...
- Hepatology Inte...
- Journal of Hepa...
- 《臨床肝膽病雜志》常見異形詞...
- 《臨床肝膽病雜志》推薦使用的規(guī)...
- 《臨床肝膽病雜志》參加2024...
- 《臨床肝膽病雜志》入選“中國科...
- 《臨床肝膽病雜志》2025年1...
- 本期審稿專家...